在DESTINY-Lung02 2期试验中，ENHERTU®在先前治疗的HER2突变型晚期癌症中显示出强大而持久的肿瘤反应

ENHERTU ® Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung Cancer in DESTINY-Lung02 Phase 2 Trial

businesswire 等信源发布 2023-09-11 14:35



可切换为仅中文







微信扫码分享